Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol-bisbenzonitrile in vitro

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2009-02-07

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00280-009-0935-7PMID 19198839PMCID PMC2774495
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Letrozole

  2012influential reference
• Comprehensive In Vitro Analysis of Voriconazole Inhibition of Eight Cytochrome P450 (CYP) Enzymes: Major Effect on CYPs 2B6, 2C9, 2C19, and 3A

  2008cited by this paper
• Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer

  2008cited by this paper
• Amodiaquine Metabolism is Impaired by Common Polymorphisms in CYP2C8: Implications for Malaria Treatment in Africa

  2007cited by this paper
• The discovery and mechanism of action of letrozole

  2007cited by this paper
• Biotransformation of letrozole in rat liver microsomes: effects of gender and tamoxifen.

  2007cited by this paper
• RANKL-dependent and RANKL-independent mechanisms of macrophage-osteoclast differentiation in breast cancer

  2007cited by this paper
• Estrogen carcinogenesis in breast cancer.

  2006cited by this paper
• Fulvestrant: Pharmacologic Profile Versus Existing Endocrine Agents for the Treatment of Breast Cancer

  2006cited by this paper
• Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment

  2006cited by this paper
• DIFFERENTIAL MECHANISM-BASED INHIBITION OF CYP3A4 AND CYP3A5 BY VERAPAMIL

  2005cited by this paper
• A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

  2005cited by this paper
• In vitro letrozole N‐dealkylation is mainly catalyzed by human cytochrome P450 (CYP) 3A

  2005cited by this paper
• Assessment of ethnic differences in the pharmacokinetics of valsartan

  2005cited by this paper
• CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

  2005cited by this paper
• A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer*

  2004cited by this paper
• Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands

  2004cited by this paper
• Aromatase inhibitors in breast cancer.

  2003cited by this paper
• The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity

  2003cited by this paper
• CYP2A6 genetic variation and potential consequences.

  2002cited by this paper
• Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate.

  2002cited by this paper
• Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara®) in breast cancer patients

  2001influential reference
• Effects of the Antifungal Agents on Oxidative Drug Metabolism

  2000cited by this paper
• Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.

  2000cited by this paper
• Gender difference in letrozole pharmacokinetics in rats.

  2000cited by this paper
• Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.

  1999cited by this paper
• Identification and characterization of human cytochrome P450 isoforms interacting with pimozide.

  1998cited by this paper
• Tamoxifen in the treatment of breast cancer.

  1998cited by this paper
• Tamoxifen in the Treatment of Breast Cancer

  1998cited by this paper
• Plasma Protein Binding of Letrozole, a New Nonsteroidal Aromatase Enzyme Inhibitor

  1998cited by this paper
• Absolute bioavailability of letrozole in healthy postmenopausal women

  1997influential reference
• Inhibition of coumarin 7-hydroxylase activity in human liver microsomes.

  1997influential reference
• Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.

  1997cited by this paper
• Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.

  1997cited by this paper
• Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.

  1996cited by this paper
• Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation.

  1992cited by this paper
• An improved assay of 7-ethoxycoumarin O-deethylase activity: induction of hepatic enzyme activity in C57BL/6J and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2,3,7,8-tetrachlorodibenzo-p-dioxin.

  1978cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• Biological aromatization of steroids.

  1959cited by this paper

• CYP3A4‐Mediated Metabolism and Drug–Drug Interaction Potential of Abemaciclib and Letrozole In Vitro

  2026cites this paper
• Treatment of ER-positive breast cancer with FDA-approved aromatase inhibitors.

  2026cites this paper
• Aromatase Inhibitor Therapy Is Associated with Distinct Plasma Lipidomic Profiles in Postmenopausal Breast Cancer Patients.

  2026cites this paper
• Exploring the roles of cytochrome P450 enzymes and their inhibitors in cancers and non-neoplastic human diseases

  2025cites this paper
• Inhibition of CYP2A6-mediated nicotine metabolism: A potential strategy for smoking cessation therapy.

  2025cites this paper
• Mechanistic Insights into CYP2A6 Inactivation by Visnagin and Its Impact on Pharmacokinetic Properties of Tegafur.

  2025cites this paper
• Systematic Review of Naturally Derived Substances That Act as Inhibitors of the Nicotine Metabolizing Enzyme Cytochrome P450 2A6

  2024cites this paper
• Development of an efficient insecticide substrate and inhibitor screening system of insect P450s using fission yeast.

  2023cites this paper
• A Rare Presentation of Metastatic Breast Cancer Manifesting As Diffuse Nodular Skin Lesions

  2023influential citation
• Pyridine based dual binding site aromatase (CYP19A1) inhibitors

  2023cites this paper
• Enriching Medication Review with a Pharmacogenetic Profile – A Case of Tamoxifen Adverse Drug Reactions

  2021cites this paper
• PGPM_A_285807 279..286

  2021cites this paper
• Towards an Understanding of the Mode of Action of Human Aromatase Activity for Azoles through Quantum Chemical Descriptors-Based Regression and Structure Activity Relationship Modeling Analysis

  2020cites this paper
• Interaction Between Cyclosporine and Palbociclib in a Renal Transplant Patient: Case Report and Pharmacokinetic Perspective

  2020cites this paper
• Inhibition and induction of CYP enzymes in humans: an update

  2020cites this paper
• Quantitative comparative analysis uncovered the role of E2 in Nile tilapia GSD + TE

  2020cites this paper
• Genetic Underpinnings of Musculoskeletal Pain During Treatment With Aromatase Inhibitors for Breast Cancer: A Biological Pathway Analysis

  2019cites this paper
• Comparison of congenital malformations among babies born after administration of letrozole or clomiphene citrate for infertility treatment in a Korean cohort.

  2018cites this paper
• Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers

  2017cites this paper
• Comprehensive and Automated Linear Interaction Energy Based Binding-Affinity Prediction for Multifarious Cytochrome P450 Aromatase Inhibitors

  2017cites this paper
• The use of aromatase inhibitors in boys with short stature: what to know before prescribing?

  2017cites this paper
• Characterization of Maternal and Fetal CYP3A-Mediated Progesterone Metabolism

  2017influential citation
• DFT computations on the hydrogen bonding interactions between methacrylic acid-trimethylolpropane trimethacrylate copolymers and letrozole as drug delivery systems

  2016cites this paper
• CYP1A2 – a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients

  2016cites this paper
• Androgen-metabolizing enzymes: A structural perspective.

  2016cites this paper
• Possible interaction between letrozole and long-acting injectable zuclopenthixol

  2015cites this paper
• 10. Phase 1–Phase 3 Clinical Studies, Procedures, Responsibilities, and Documentation

  2015cites this paper
• Determining the IC50 Values for Vorozole and Letrozole, on a Series of Human Liver Cytochrome P450s, to Help Determine the Binding Site of Vorozole in the Liver

  2015cites this paper
• Computational studies on the anastrozole and letrozole, effective chemotherapy drugs against breast cancer.

  2014cites this paper
• Inhibition of Cytochrome P450 Enzymes by the E -, and Z -Isomers of Norendoxifen

  2013cites this paper
• Inhibition of Cytochrome P450 Enzymes by the E - and Z -Isomers of Norendoxifen

  2013cites this paper
• Inhibition of Cytochrome P450 Enzymes by the E- and Z-Isomers of Norendoxifen

  2013cites this paper
• Inhibition of Cytochrome P450 Enzymes by the E -, and Z -Isomers of Norendoxifen

  2013cites this paper
• Inhibition of Cytochrome P450 Enzymes by the E - and Z -Isomers of Norendoxifen

  2013cites this paper
• Role for endogenous estrogen in prepubertal Sertoli cell maturation.

  2012cites this paper
• Reduced Methadone Clearance During Aromatase Inhibition

  2012cites this paper
• QUANTIFICATION OF LETROZOLE IN HUMAN PLASMA USING LC-(–)ESI-MS/MS WITH D4-LETROZOLE AS INTERNAL STANDARD: APPLICATION IN A PHARMACOKINETIC STUDY

  2012cites this paper
• Novel aromatase inhibitors by structure-guided design.

  2012cites this paper
• Letrozole: Advancing Hormone Therapy in Breast Cancer

  2012cites this paper
• PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6

  2012cites this paper
• New approach to analyze genetic and clinical data in bisphosphonate-induced osteonecrosis of the jaw.

  2012cites this paper
• PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8

  2012cites this paper
• In Vitro Evaluation of the Interaction Potential of Irosustat with Drug-Metabolizing Enzymes

  2012influential citation
• Understanding Aromatase: A Mechanistic Basis for Drug Interactions and New Inhibitors

  2012cites this paper
• Pharmacogenomics of third-generation aromatase inhibitors

  2012cites this paper
• The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents

  2012cites this paper
• Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age

  2011cites this paper
• Alternative Androgen Metabolism in Resistance to Aromatase Inhibitors.

  2011cites this paper
• Microsoft Word-41261660-file00

  2010cites this paper
• Efavirenz Primary and Secondary Metabolism In Vitro and In Vivo: Identification of Novel Metabolic Pathways and Cytochrome P450 2A6 as the Principal Catalyst of Efavirenz 7-Hydroxylation

  2010cites this paper
• Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes

  2009cites this paper